Holen Sie sich die Stockscreener-App
1.23
0.00%
0.00
Handel nachbörslich:
1.21
-0.02
-1.63%
Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten
HC Wainwright Issues Pessimistic Forecast for SGMO Earnings - MarketBeat
Sangamo Therapeutics' (SGMO) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
HC Wainwright Has Bearish Outlook for SGMO FY2024 Earnings - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc.SGMO - The Eastern Progress Online
Sangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC Wainwright - Defense World
Sangamo Therapeutics' (SGMO) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts - Benzinga
Truist Financial Has Lowered Expectations for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World
Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) PT at $5.17 - MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Truist Financial Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $5.00 - MarketBeat
Sangamo Therapeutics Stock Slips On Termination of Pfizer Collaboration: Retail’s Cautious - MSN
Sangamo Nearing Fabry Gene Therapy Deal To Fund Its Pipeline - News & Insights
Top 5 NASDAQ Genetics Stocks (Updated January 2025) - Nasdaq
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025 - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation - AccessWire
Sangamo Q3 2018 First Look: Dancing With Data (NASDAQ:SGMO) - Seeking Alpha
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal - MSN
Sangamo Therapeutics Shares Plunge 50% After Pfizer Pulls Out of Hemophilia Drug Deal – Market - HPBL
WASATCH ADVISORS LP Reduces Stake in Sangamo Therapeutics Inc - GuruFocus.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation - AccessWire
15 Small-Cap Stocks Poised to Outperform in 2025 - Insider Monkey
Sangamo to regain rights to hemophilia A gene therapy - Hemophilia News Today
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect - AccessWire
Hemoglobinopathies Market Projected to Show Strong Growth| - openPR
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
State Street Corp Grows Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More - Zacks Investment Research
Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership - MSN
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces pivotal year By Investing.com - Investing.com South Africa
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces pivotal year - Investing.com India
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals - BioPharma Dive
Sangamo Therapeutics’ SWOT analysis: gene therapy firm’s stock faces pivotal year - Investing.com Nigeria
Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal - MSN
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
Sangamo spirals after Pfizer halts hemophilia A gene therapy partnership - MM+M Online
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation - AccessWire
Sangamo Therapeutics (NASDAQ:SGMO) Given "Buy" Rating at HC Wainwright - MarketBeat
Sangamo Therapeutics to Regain Rights to Gene Therapy Program from Pfizer - Contract Pharma
Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Partnership - Barron's
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):